About this ETF
Invesco Exchange-Traded Fund Trust II - Invesco S&P SmallCap Health Care ETF is an exchange traded fund launched and managed by Invesco Capital Management LLC. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care sectors. It invests in growth and value stocks of small-cap companies. It seeks to track the performance of the S&P SmallCap 600 Capped Health Care Index, by using full replication technique. Invesco Exchange-Traded Fund Trust II - Invesco S&P SmallCap Health Care ETF was formed on April 7, 2010 and is domiciled in the United States.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +5.19% | +24.27% | +29.05% | +26.42% | +37.12% | +10.79% | -2.12% | +8.67% | +12.27% |
| Total return | +5.19% | +24.27% | +29.05% | +26.42% | +37.12% | +10.90% | -2.06% | +8.72% | +12.49% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.29% | Annual cost of a $10,000 investment | $29.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 75 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Corcept Therapeutics Inc | CORT | 5.83% | 89.84K | $10.9M |
| 2 | Glaukos Corp | GKOS | 5.47% | 55.21K | $10.2M |
| 3 | Protagonist Therapeutics Inc | PTGX | 4.59% | 56.83K | $8.6M |
| 4 | Alkermes PLC | ALKS | 4.03% | 156.72K | $7.5M |
| 5 | TG Therapeutics Inc | TGTX | 3.36% | 123.93K | $6.3M |
| 6 | Teleflex Inc | TFX | 3.01% | 41.62K | $5.6M |
| 7 | PTC Therapeutics Inc | PTCT | 2.95% | 78.00K | $5.5M |
| 8 | Ligand Pharmaceuticals Inc | LGND | 2.90% | 18.85K | $5.4M |
| 9 | RadNet Inc | RDNT | 2.75% | 66.54K | $5.1M |
| 10 | Merit Medical Systems Inc | MMSI | 2.71% | 56.09K | $5.1M |
| 11 | Liquidia Corp | LQDA | 2.51% | 66.04K | $4.7M |
| 12 | Indivior Pharmaceuticals Inc | INDV | 2.32% | 114.63K | $4.3M |
| 13 | ICU Medical Inc | ICUI | 2.30% | 23.51K | $4.3M |
| 14 | Integer Holdings Corp | ITGR | 2.14% | 31.91K | $4.0M |
| 15 | Concentra Group Holdings Parent Inc | CON | 2.09% | 111.89K | $3.9M |
| 16 | ACADIA Pharmaceuticals Inc | ACAD | 1.85% | 119.12K | $3.5M |
| 17 | Organon & Co | OGN | 1.82% | 246.88K | $3.4M |
| 18 | Veracyte Inc | VCYT | 1.68% | 75.02K | $3.1M |
| 19 | TransMedics Group Inc | TMDX | 1.58% | 32.49K | $3.0M |
| 20 | Amneal Pharmaceuticals Inc | AMRX | 1.55% | 161.97K | $2.9M |
| 21 | National HealthCare Corp | NHC | 1.49% | 11.76K | $2.8M |
| 22 | LifeStance Health Group Inc | LFST | 1.46% | 215.39K | $2.7M |
| 23 | Waystar Holding Corp | WAY | 1.44% | 108.20K | $2.7M |
| 24 | Supernus Pharmaceuticals Inc | SUPN | 1.39% | 54.56K | $2.6M |
| 25 | Neogen Corp | NEOG | 1.30% | 204.64K | $2.4M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.01% | Paid (last 12 months) | $0.0029 |
| Frequency | Semi-Annual | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Mar 23, 2026 | Last payment | $0.0003 (Mar 27, 2026) |
| Growth 1Y | -91.46% | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Mar 23, 2026 | Mar 23, 2026 | Mar 27, 2026 | $0.0003 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 26, 2025 | $0.0026 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 27, 2025 | $0.0020 |
| Mar 24, 2025 | Mar 24, 2025 | Mar 28, 2025 | $0.0142 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 27, 2024 | $0.0180 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 28, 2024 | $0.0659 |
| Mar 18, 2024 | Mar 19, 2024 | Mar 22, 2024 | $0.0361 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 22, 2023 | $0.0045 |
| Sep 24, 2018 | Sep 25, 2018 | Sep 28, 2018 | $0.0052 |
| Dec 16, 2016 | Dec 20, 2016 | Dec 30, 2016 | $0.0195 |
| Dec 24, 2014 | Dec 29, 2014 | Dec 31, 2014 | $1.4406 |
| Dec 19, 2014 | Dec 23, 2014 | Dec 31, 2014 | $0.0276 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 19.59% / 22.05% | Sharpe 1Y / 3Y | 1.85 / 0.453 |
| Max drawdown 1Y / 3Y | -15.36% / -23.00% | Sortino 1Y | 2.96 |
| Beta vs S&P 500 (3Y) | 0.923 | Correlation vs S&P 500 (1Y) | 0.561 |
| Downside deviation 1Y | 12.25% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 6.80K | Average volume | 21.43K |
| AUM | $189.9M | Premium/Discount | -0.11% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$615.1K | -0.32% | $190.2M → $189.6M |
| 1 Week | $4.6M | +2.44% | $186.8M → $189.6M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for PSCH
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.
PSCH